BioCentury on BioBusiness,
Emerging Company Profile
ObeSys: killer of fat cells
Monday, December 4, 1995
Emerging Company Profile
ObeSys: killer of fat cellsAs everyone who has ever slid gracefully into middle age knows, little pockets of fat take up residence that even a starvation diet can't eliminate. Among the growing number of companies focused on obesity, ObeSys Inc. has the potential to target adipocytes - those fat cells - both systemically and on a selective basis via direct injection.
The London company was formed in 1994 based on the convergence of two technologies: an immunological approach to the killing of adipocytes developed in the agricultural sector, and the maturation of technology for making human or humanized antibodies. The company's goal is to develop a systemic treatment for obesity based on complement-mediated lysis of adipocytes by human or humanized antibodies. Site-specific "biological liposuction" would complement other anti-obesity treatments in development.
'New areas'"Antibody companies are always targeting the same thing: cancer and autoimmune disease," said Christopher Hentschel, executive chairman of the board and a founder of ObeSys. "Over a few beers we were trying to think of new areas that antibodies could be targeted to
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]